Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window People mounting ...
Please provide your email address to receive an email when new articles are posted on . Late-breaking data supported the efficacy of icotrokinra, an interleukin-23 inhibitor, for plaque psoriasis. By ...
Researchers determine the clinical and demographic risk factors of paradoxical eczema as well as the overall incidence and biologic-class-specific risk factors and incidence of paradoxical eczema in ...
Please provide your email address to receive an email when new articles are posted on . The FDA expanded the indication for Tremfya (guselkumab) to children with plaque psoriasis or active psoriatic ...
Data point to the potential of JNJ-2113 as a first-in-class drug candidate in multiple IL-23 driven-diseases Highlights of the data presented on JNJ-2113 include the following: JNJ-2113 is a ...